Voyager Therapeutics grants director 30,000 stock options

Voyager Therapeutics director George A. Scangos received a grant of stock options for 30,000 shares of common stock as director compensation.

Rhea-AI Filing Summary

Voyager Therapeutics director George A. Scangos received a grant of stock options for 30,000 shares of common stock as director compensation. The options have an exercise price of $3.43 per share and expire on June 9, 2036.

According to the company’s 2025 Stock Incentive Plan, all 30,000 underlying shares vest upon the earlier of the one-year anniversary of the grant date or the date of the next annual meeting of stockholders, assuming he continues to serve as a director. After this grant, Scangos holds 30,000 stock options directly.

Insider Trade Summary

Grant/Award: 30,000 shares

Grant/Award 1 txn

Insider SCANGOS GEORGE A

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	30,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 30,000 contracts (Direct)

Footnotes (1)

1. F1. This stock option was issued pursuant to the 2025 Stock Incentive Plan of Voyager Therapeutics, Inc. in accordance with its director compensation policy. The vesting commencement date (the "Vesting Commencement Date") of the option is the grant date. All of the shares of common stock underlying the option vest upon the earlier of the one-year anniversary of the Vesting Commencement Date or the date of the next annual meeting of stockholders, in each case subject to the Reporting Person's continued service as a director.

Key Figures

Option grant size: 30,000 options Exercise price: $3.43 per share Expiration date: June 9, 2036 +2 more

5 metrics

Option grant size 30,000 options Stock Option (Right to Buy) granted on June 9, 2026

Exercise price $3.43 per share Exercise price for 30,000 Voyager Therapeutics options

Expiration date June 9, 2036 Option expiration under 2025 Stock Incentive Plan

Underlying shares 30,000 shares Common stock underlying the stock option grant

Post-transaction options held 30,000 options Total stock options held directly after grant

Key Terms

Stock Option (Right to Buy), 2025 Stock Incentive Plan, director compensation policy, vesting commencement date, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

2025 Stock Incentive Plan financial

"This stock option was issued pursuant to the 2025 Stock Incentive Plan of Voyager Therapeutics, Inc."

director compensation policy financial

"issued pursuant to the 2025 Stock Incentive Plan ... in accordance with its director compensation policy."

vesting commencement date financial

"The vesting commencement date (the "Vesting Commencement Date") of the option is the grant date."

The vesting commencement date is the starting point when an employee begins earning ownership rights to their promised benefits, such as stock options or retirement contributions. Think of it like the day a savings account is opened—only after this date do the benefits start to grow and become fully available over time. It matters to investors because it marks when the clock begins ticking toward full ownership, affecting the timing and value of these benefits.

annual meeting of stockholders financial

"underlying the option vest upon the earlier of the one-year anniversary ... or the date of the next annual meeting of stockholders"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Voyager Therapeutics (VYGR) director George Scangos report on this Form 4?

George A. Scangos reported receiving a grant of stock options for 30,000 shares of Voyager Therapeutics common stock. The grant is compensation under the 2025 Stock Incentive Plan and not an open-market purchase or sale of existing shares.

What are the key terms of George Scangos’s Voyager Therapeutics stock option grant?

The stock option covers 30,000 shares of common stock at an exercise price of $3.43 per share, expiring on June 9, 2036. It was issued under Voyager Therapeutics’ 2025 Stock Incentive Plan as part of the director compensation policy.

How and when do George Scangos’s Voyager Therapeutics options vest?

All 30,000 shares underlying the option vest upon the earlier of the one-year anniversary of the grant date or the next annual meeting of stockholders. Vesting requires George Scangos to continue serving as a director through that date.

Did Voyager Therapeutics (VYGR) director George Scangos buy or sell shares in the market?

He did not buy or sell shares in the open market. The Form 4 reports a compensation-related grant of stock options, giving him the right to buy 30,000 shares at $3.43 in the future, subject to vesting conditions.

How many Voyager Therapeutics options does George Scangos hold after this grant?

Following this transaction, George Scangos holds stock options covering 30,000 shares of Voyager Therapeutics common stock directly. The filing does not show additional derivative positions beyond this new grant in the derivative summary section.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/11/2026 - 04:05 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SCANGOS GEORGE A

(Last) (First) (Middle)

C/O VOYAGER THERAPEUTICS, INC.

75 HAYDEN AVENUE

(Street)

LEXINGTON MASSACHUSETTS 02421

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Voyager Therapeutics, Inc. [ VYGR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$3.43	06/09/2026		A		30,000		(1)	06/09/2036	Common Stock	30,000	$0	30,000	D

Explanation of Responses:

1. This stock option was issued pursuant to the 2025 Stock Incentive Plan of Voyager Therapeutics, Inc. in accordance with its director compensation policy. The vesting commencement date (the "Vesting Commencement Date") of the option is the grant date. All of the shares of common stock underlying the option vest upon the earlier of the one-year anniversary of the Vesting Commencement Date or the date of the next annual meeting of stockholders, in each case subject to the Reporting Person's continued service as a director.

Remarks:

Exhibit 24: Power of Attorney

	/s/ Gregory L. Shiferman, as Attorney-in-Fact for George A. Scangos	06/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)